Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Pancreatic adenocarcinoma is the 4th leading cause of cancer in the USA. Its incidence is increasing both in France and in Europe, whereas all the other cancers are decreasing in Europe. Moreover, its seriousness is still high, with a mortality rate higher than the average incidence. The aim of PAPAFA study is to assess the prevalence of the pancreatic anomalies which can be revealed thanks to imaging, for patients having a 1st degree pancreatic adenocarcinoma familial history. This could allow detection of lesions which are less than 10 mm long, and improve the dark prognostic of this pathology.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Single arm | Other | Pancreatic MRI in the 6 months following the first consultation |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Pancreatic MRI | Procedure | Pancreatic MRI in the 6 months following the first consultation |
|
| Measure | Description | Time Frame |
|---|---|---|
| Number of patients for whom the MRI and/or the echo endoscopy has shown a parenchymatous or ductal pancreatic anomaly | For every patients who will have a pancreatic MRI detecting an anomaly, the echo endoscopy will be done. A cytology of the lesion from the echo endoscopy will be done for the solid lesions and for the indetermined cystic lesions (that is to say, the lesions which don't meet the literature set criteria for serous kyst or intraductal papillary and mucinous tumor of the pancreas) ; which is usually done in health care. | six months after the last inclusion |
| Measure | Description | Time Frame |
|---|---|---|
| Number of patients for whom the MRI has brought to light a parenchymatous and/or ductal pancreatic anomaly | six months after the last inclusion | |
| Number of patients for whom the echo endoscopy has brought to light a parenchymatous and/or ductal pancreatic anomaly |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Anne-marie Marion Audibert | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Clinique Convert | Bourg-en-Bresse | France | ||||
| Infirmerie Protestante |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| six months after the last inclusion |
| Height of the lesions | six months after the last inclusion |
| Correlation between the data from the MRI and those from the echo endoscopy | six months after the last inclusion |
| Localisation of the lesions | six months after the last inclusion |
| Number of lesions | six months after the last inclusion |
| Aspect of the lesion (solid and/or liquid) | six months after the last inclusion |
| Caluire-et-Cuire |
| 69300 |
| France |
| Clinique du Val d'Ouest | Écully | 69130 | France |
| Groupe Hospitalier Mutualiste des Eaux Claires | Grenoble | 38028 | France |
| Centre des maladies du foie et de l'appareil digestif | Irigny | France |
| Centre Hospitalier Saint Joseph Saint Luc | Lyon | 69007 | France |
| Hôpital privé Jean Mermoz | Lyon | 69008 | France |
| Clinique des Portes du Sud | Vénissieux | 69694 | France |
| Hôpital de Villefranche | Villefranche-sur-Saône | 69655 | France |
| ID | Term |
|---|---|
| D000230 | Adenocarcinoma |
| ID | Term |
|---|---|
| D002277 | Carcinoma |
| D009375 | Neoplasms, Glandular and Epithelial |
| D009370 | Neoplasms by Histologic Type |
| D009369 | Neoplasms |
Not provided
Not provided